Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amylon Therapeutics B.V.

https://amylon.com/

Latest From Amylon Therapeutics B.V.

30 Rising Leaders In The Life Sciences

Revealed: In Vivo’s list of 30 Rising Leaders across the biopharma, medtech and health technology sectors. Find out who made the cut. 

Business Strategies Commercial

Biopharma Quarterly Dealmaking Statistics, Q3 2017

Third-quarter biopharma financing, which totaled $12.5 billion, was dominated by follow-on public offerings, which represented virtually half the value. Acquisition activity was headlined by a major move by Gilead in the CART market. Five alliances were signed worth over $1 billion, led by a partnership between two key players, Merck & Co. and AstraZeneca.

BioPharmaceutical Deals

Venture Funding Deals: Spin-Offs Gain Their Own Footing

Pfizer-backed SpringWorks, ProQR spin-out Amylon and Landos, the first firm out of accelerator Xontogeny, gain their own financing. Other venture rounds support Autolus, Grid Therapeutics, Excision and more.

Deals StartUps and SMEs

Deal Watch: Are Ultragenyx, REGENXBIO In A Bidding War For Dimension?

ProQR spinout Amylon gets started by licensing four central nervous system disorder candidates from its parent, while start-up Eyevance gets US rights to Nicox’s Zerviate.

Deals M & A
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Other Names / Subsidiaries
    • ProQR
UsernamePublicRestriction

Register